Cutaneous Leishmaniasis, Scar
Conditions
Keywords
Paromomycin, Gentamicin
Brief summary
Primary Objectives: Assess whether CL (caused by Leishmaniasis major) lesions treated with WR279396 improved the cosmetic outcome compared with no treatment (natural healing)
Detailed description
Secondary Objectives 1. Evaluate the cosmetic outcome of CL lesions treated with vehicle compared with no treatment (natural healing) 2. Evaluate the cosmetic outcome of CL lesions treated with vehicle compared with WR279396 * To determine whether CL lesions treated with vehicle improves the cosmetic outcome (compared with natural healing) * To determine whether CL lesions treated with vehicle alone provides a cosmetic outcome similar to WR279396
Interventions
DRUGWR 279396
Sponsors
Institut Pasteur
U.S. Army Medical Research and Development Command
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
5 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Included are volunteers who participated in WRAIR 813 (HSRRB Log # 9768.1) and those who participated in another CL study in/around the WRAIR 813 study site who had been assigned to a no-treatment (natural healing) arm. All volunteers will have had documented CL in the past that were treated with WR279396, vehicle, or no treatment (natural history), have signed informed consent, and are willing to comply with study assessments; age range: 5 to 75 years old. * For study subjects who were enrolled in WRAIR 813 in 2004 (WR279396 or vehicle treated): * Written informed consent obtained from the subject or guardian * Willing to meet the requirements of the single clinic visit * Prior data in the clinical site data base documenting a diagnosis of CL * Each lesion for inclusion in this study conforms to WRAIR 813: ³ 1 cm in diameter and was primarily ulcerative (i.e., not verrucous or nodular) * The index lesion and others to be scored were proven parasitologically by Giemsa slide smear * CL scars documented to be \> 360 days old (clock starts at time of diagnosis) * No treatment of the lesions other than that received in the previous protocol * Study subjects from the earlier studies to serve as no treatment controls: * Written informed consent obtained from the subject or guardian * Willing to meet the requirements of the single clinic visit * Same age range as WRAIR 813: 5-75 years old at time of diagnosis * Prior data in the clinical site data base documenting a diagnosis of CL, and that the volunteer was assigned to the no treatment group * Each lesion for inclusion in this study will conform to WRAIR 813: at the time of diagnosis, ≥1 cm in diameter and described as primarily ulcerative (i.e., not verrucous or nodular) * At least 1 lesion that was proven parasitologically by Giemsa slide smear for inclusion in the earlier study. * CL scars documented to be \> 360 days old (clock starts at time of diagnosis) * Never received any treatment of the lesions (natural healing) or applied any medication, such as herbal medication * Lesions present on the trunk or extremities, to match the WRAIR 813 study volunteers (no facial lesions were treated in the 2004 study)
Exclusion criteria
* Potential volunteers without a prior documented diagnosis of CL
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cosmetic outcome based on modified Vancouver Scar Score (mVSS) | Day 360 or greater | The primary cosmetic outcome measure is the Clinical Scar Rating, based on a modified Vancouver Scar Score (mVSS). The primary efficacy endpoint is the percent of persons judged to have either a superior (no scar) or excellent rating (see below). |
Countries
Tunisia
Outcome results
None listed